These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

460 related articles for article (PubMed ID: 20101721)

  • 21. Transgenic mouse models of Alzheimer's disease.
    Hock BJ; Lamb BT
    Trends Genet; 2001 Oct; 17(10):S7-12. PubMed ID: 11585670
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intensive 'Brain Training' Intervention Fails to Reduce Amyloid Pathologies or Cognitive Deficits in Transgenic Mouse Models of Alzheimer's Disease.
    Anderson M; Xu F; Ou-Yang MH; Davis J; Van Nostrand WE; Robinson JK
    J Alzheimers Dis; 2017; 55(3):1109-1121. PubMed ID: 27767989
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Amyloid-induced neurofibrillary tangle formation in Alzheimer's disease: insight from transgenic mouse and tissue-culture models.
    Götz J; Schild A; Hoerndli F; Pennanen L
    Int J Dev Neurosci; 2004 Nov; 22(7):453-65. PubMed ID: 15465275
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fibrillar Aβ triggers microglial proteome alterations and dysfunction in Alzheimer mouse models.
    Sebastian Monasor L; Müller SA; Colombo AV; Tanrioever G; König J; Roth S; Liesz A; Berghofer A; Piechotta A; Prestel M; Saito T; Saido TC; Herms J; Willem M; Haass C; Lichtenthaler SF; Tahirovic S
    Elife; 2020 Jun; 9():. PubMed ID: 32510331
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A decade of modeling Alzheimer's disease in transgenic mice.
    McGowan E; Eriksen J; Hutton M
    Trends Genet; 2006 May; 22(5):281-9. PubMed ID: 16567017
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Progressive accumulation of amyloid-beta oligomers in Alzheimer's disease and in amyloid precursor protein transgenic mice is accompanied by selective alterations in synaptic scaffold proteins.
    Pham E; Crews L; Ubhi K; Hansen L; Adame A; Cartier A; Salmon D; Galasko D; Michael S; Savas JN; Yates JR; Glabe C; Masliah E
    FEBS J; 2010 Jul; 277(14):3051-67. PubMed ID: 20573181
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Environmental novelty exacerbates stress hormones and Aβ pathology in an Alzheimer's model.
    Stuart KE; King AE; Fernandez-Martos CM; Summers MJ; Vickers JC
    Sci Rep; 2017 Jun; 7(1):2764. PubMed ID: 28584278
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Chronic gliosis triggers Alzheimer's disease-like processing of amyloid precursor protein.
    Bates KA; Fonte J; Robertson TA; Martins RN; Harvey AR
    Neuroscience; 2002; 113(4):785-96. PubMed ID: 12182886
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Outstanding Phenotypic Differences in the Profile of Amyloid-β between Tg2576 and APPswe/PS1dE9 Transgenic Mouse Models of Alzheimer's Disease.
    Allué JA; Sarasa L; Izco M; Pérez-Grijalba V; Fandos N; Pascual-Lucas M; Ogueta S; Pesini P; Sarasa M
    J Alzheimers Dis; 2016 May; 53(3):773-85. PubMed ID: 27258422
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An Animal Model to Test Reversal of Cognitive Decline Associated with Beta-Amyloid Pathologies.
    Deba F; Peterson S; Hamouda AK
    Methods Mol Biol; 2019; 2011():393-412. PubMed ID: 31273712
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Brain ischemia with Alzheimer phenotype dysregulates Alzheimer's disease-related proteins.
    Ułamek-Kozioł M; Pluta R; Bogucka-Kocka A; Januszewski S; Kocki J; Czuczwar SJ
    Pharmacol Rep; 2016 Jun; 68(3):582-91. PubMed ID: 26940197
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Genetic reductions of beta-site amyloid precursor protein-cleaving enzyme 1 and amyloid-beta ameliorate impairment of conditioned taste aversion memory in 5XFAD Alzheimer's disease model mice.
    Devi L; Ohno M
    Eur J Neurosci; 2010 Jan; 31(1):110-8. PubMed ID: 20092558
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Magnetic resonance imaging of Alzheimer's pathology in the brains of living transgenic mice: a new tool in Alzheimer's disease research.
    Jack CR; Marjanska M; Wengenack TM; Reyes DA; Curran GL; Lin J; Preboske GM; Poduslo JF; Garwood M
    Neuroscientist; 2007 Feb; 13(1):38-48. PubMed ID: 17229974
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mutation-induced loss of APP function causes GABAergic depletion in recessive familial Alzheimer's disease: analysis of Osaka mutation-knockin mice.
    Umeda T; Kimura T; Yoshida K; Takao K; Fujita Y; Matsuyama S; Sakai A; Yamashita M; Yamashita Y; Ohnishi K; Suzuki M; Takuma H; Miyakawa T; Takashima A; Morita T; Mori H; Tomiyama T
    Acta Neuropathol Commun; 2017 Jul; 5(1):59. PubMed ID: 28760161
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Recent work on Alzheimer's disease transgenics.
    Duff K
    Curr Opin Biotechnol; 1998 Dec; 9(6):561-4. PubMed ID: 9889140
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Biological transgenic mouse models of Alzheimer's disease.
    Crews L; Rockenstein E; Masliah E
    Handb Clin Neurol; 2008; 89():291-301. PubMed ID: 18631753
    [No Abstract]   [Full Text] [Related]  

  • 37. APP Osaka Mutation in Familial Alzheimer's Disease-Its Discovery, Phenotypes, and Mechanism of Recessive Inheritance.
    Tomiyama T; Shimada H
    Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32093100
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Modeling the β-secretase cleavage site and humanizing amyloid-beta precursor protein in rat and mouse to study Alzheimer's disease.
    Serneels L; T'Syen D; Perez-Benito L; Theys T; Holt MG; De Strooper B
    Mol Neurodegener; 2020 Oct; 15(1):60. PubMed ID: 33076948
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-Term Treatment with Liraglutide, a Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist, Has No Effect on β-Amyloid Plaque Load in Two Transgenic APP/PS1 Mouse Models of Alzheimer's Disease.
    Hansen HH; Fabricius K; Barkholt P; Kongsbak-Wismann P; Schlumberger C; Jelsing J; Terwel D; Termont A; Pyke C; Knudsen LB; Vrang N
    PLoS One; 2016; 11(7):e0158205. PubMed ID: 27421117
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Kv1.3 inhibition as a potential microglia-targeted therapy for Alzheimer's disease: preclinical proof of concept.
    Maezawa I; Nguyen HM; Di Lucente J; Jenkins DP; Singh V; Hilt S; Kim K; Rangaraju S; Levey AI; Wulff H; Jin LW
    Brain; 2018 Feb; 141(2):596-612. PubMed ID: 29272333
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.